SCHEMBL579199

SCHEMBL579199

NC(=O)c1c(F)n(-c2ccccc2)c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
ATM Q13315 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
EGFR P00533 2/20 0.45
SRC P12931 1/20 0.45
REN P00797 8/20 0.42
PLA2G2A P14555 1/20 0.42
FOLH1 Q04609 1/20 0.41
KMT2A Q03164 1/20 0.41
PTK2B Q14289 1/20 0.40
RECQL P46063 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
RORC P51449 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.38
GFER P55789 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL579598 0.91 USP14 (0.46) KDM4EATML3MBTL1EGFRSRC
SCHEMBL17883617 0.81 HKDC1 (0.43) KDM4EATML3MBTL1EGFRSRC
SCHEMBL28295413 0.81 GAA (0.55) KDM4EATML3MBTL1EGFRSRC
SCHEMBL4565589 0.80 EGFR (0.42) KDM4EL3MBTL1EGFRSRCREN
SCHEMBL28285344 0.79 IL1R1 (0.54) KDM4EATML3MBTL1EGFRSRC
SCHEMBL27286581 0.79 KDM4E (0.47) KDM4EATML3MBTL1FOLH1KMT2A
Hydrochloric Acid SCHEMBL28283710 0.78 ALDH1A1 (0.55) KDM4EATML3MBTL1EGFRSRC
SCHEMBL18614818 0.78 EGFR (0.49) KDM4EL3MBTL1EGFRSRCKMT2A
SCHEMBL28246991 0.77 EGFR (0.64) KDM4EATML3MBTL1EGFRSRC
SCHEMBL28285318 0.75 IL1R1 (0.46) KDM4EATML3MBTL1EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735414-B2 Indole derivatives and methods for antiviral treatment PTC THERAPEUTICS, INC. (US) 2014-05-27 US disclosed
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC THERAPEUTICS, INC. (US) 2012-07-19 US disclosed
EP-2417122-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC Therapeutics, Inc. (US) 2012-02-15 EP disclosed
WO-2010117932-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT IDO1, IRF3, MAVS KDM4E 886/4885ATM 3658/4885L3MBTL1 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.